MRC1 and colorectal cancer: The NICHE study examined the role of the neoadjuvant combination of ipilimumab and nivolumab in early colorectal cancer, showing a pathological response in 20/20 patients with MMR-deficient disease, including 12 complete pathological responses, while only 4/15 patients with MMR-intact disease had a pathological response [101].